Our partners
Birmingham Drug Discovery Hub
beLAB1407 provides drug discovery resources and expertise, thereby significantly reducing timelines and ensuring a greater success rate for emerging therapeutic concepts to reach preclinical and clinical proof-of-concept. beLAB1407 catalyse innovation to create sustainable companies.
beLAB1407 is a partnership between the University of Birmingham and six other leading universities, Evotec and Bristol Myers Squibb (BMS), to identify exciting and novel disease modifying therapeutic targets and platforms with the goal to develop these into new spinout companies.